Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

torrent pharmaceuticals limited - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules are indicated for the treatment of: - major depressive disorder in adults - generalized anxiety disorder in adults and pediatric patients 7 years of age and older - diabetic peripheral neuropathic pain in adults - fibromyalgia in adults and pediatric patients 13 years of age and older - chronic musculoskeletal pain in adults the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of ser

Канада - Енглески - Health Canada

biomed pharma - duloxetine (duloxetine hydrochloride) - capsule (delayed release) - 30mg - duloxetine (duloxetine hydrochloride) 30mg - selective serotonin and norepinephrine-reuptake inhibitors

Канада - Енглески - Health Canada

biomed pharma - duloxetine (duloxetine hydrochloride) - capsule (delayed release) - 60mg - duloxetine (duloxetine hydrochloride) 60mg - selective serotonin and norepinephrine-reuptake inhibitors

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

direct rx - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules usp are indicated for the treatment of: major depressive disorder [see clinical studies (14.1)] generalized anxiety disorder [see clinical studies (14.2)] diabetic peripheral neuropathy [see clinical studies (14.3)] chronic musculoskeletal pain [see clinical studies (14.5)] monoamine oxidase inhibitors (maois) — the use of maois intended to treat psychiatric disorders with duloxetine or within 5 days of stopping treatment with duloxetine is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.9) and warnings and precautions

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose; purified talc; gelatin; sucrose; indigo carmine; hypromellose phthalate; triethyl citrate; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad). duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: titanium dioxide; gelatin; hypromellose; purified talc; hypromellose phthalate; triethyl citrate; indigo carmine; sucrose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: titanium dioxide; crospovidone; hypromellose phthalate; hypromellose; triethyl citrate; purified talc; hyprolose; maize starch; sucrose; indigo carmine; purified water; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - duloxetine hydrochloride, quantity: 67.32 mg (equivalent: duloxetine, qty 60 mg) - capsule, enteric - excipient ingredients: purified talc; crospovidone; titanium dioxide; hyprolose; hypromellose phthalate; hypromellose; triethyl citrate; indigo carmine; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

tya pharmaceuticals - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 60 mg - duloxetine delayed-release capsules usp are indicated for the treatment of major depressive disorder (mdd). the efficacy of duloxetine delayed-release capsules usp was established in four short-term and one maintenance trial in adults [ ]. see clinical studies ( ) 14.1 a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. duloxetine delayed-release capsules usp are indicated for the treatment of generalized anxiety disorder (gad). the efficacy

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules are indicated for the treatment of: • major depressive disorder [see clinical studies (14.1)] • generalized anxiety disorder [see clinical studies (14.2)] • diabetic peripheral neuropathy [see clinical studies (14.3)] • chronic musculoskeletal pain [see clinical studies (14.5)] monoamine oxidase inhibitors (maois) — the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increa